Seeking Alpha
13 Nov 2026, 18:48 UTC · 1h ago
DiaMedica Therapeutics Inc. (DMAC) Q3 2026 Earnings Call Transcript
Impact · against what's priced in
DiaMedica has reached critical clinical milestones by completing enrollment for ReMEDy2 and early cohorts of its fetal growth restriction study. These achievements accelerate the timeline toward a Phase II readout in 2027 and diversify the clinical pipeline.
- DMAC+0.50
No priced-in read yet
- In context
The company reached the 200-participant mark in the ReMEDy2 study and completed enrollment for the first two cohorts of its fetal growth restriction study, moving it closer to 2027 data readouts.
Read from the article alone
Search tags
